A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Phase 1

Completed

• Conditions: Sleep Apnea
• Interventions: Drug: VI-0521; Drug: placebo

• Registration Number: NCT00745251
• Lead Sponsor: VIVUS LLC

Brief Summary

The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight loss on parameters of OSA in these subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2008-08-31
• Study First Submitted QC: 2008-08-31
• Study First Posted: 2008-09-03
• Primary Completion: 2009-09
• Study Completion: 2009-12
• Disposition First Submitted: 2011-05-13
• Disposition First Submitted QC: 2011-05-13
• Disposition First Posted: 2011-05-18
• Results First Submitted: 2012-07-31
• Status Verified: 2012-09
• Results First Submitted QC: 2012-09-05
• Last Update Submitted: 2012-09-05
• Results First Posted: 2012-10-05
• Last Update Posted: 2012-10-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Obese adults 30 - 65 years old (inclusive);
• Women of child-bearing potential must be using adequate contraception;
• BMI between 30 and 40 kg/m2 (inclusive);
• Diagnosis of OSA syndrome with Apnea/Hypopnea Index (AHI) of 15 or greater;
• Unwilling or unable to comply with CPAP treatment;

Exclusion Criteria

• Known allergy or hypersensitivity to phentermine or topiramate;
• Sleep disorder other than OSA syndrome;
• Women who are pregnant, breast feeding, or intend to become pregnant during the study;
• Presence of unstable angina or heart failure corresponding to NYHA functional class III or IV;
• History of myocardial infarction or coronary revascularization within the past year; any history of stroke;
• Presence of any clinically significant abnormality on electrocardiogram;
• Use of any prescription CNS stimulants;
• History of cholecystitis or cholelithiasis unless treated by cholecystectomy;
• History of glaucoma or any past or present use of medications to treat increased intraocular pressure;
• Weight gain or loss of greater than 5 kg, use of a very low-calorie diet, or participation in a formal weight loss program (investigational or otherwise) within the past 3 months;
• Previous bariatric surgery;
• Shift workers or any subjects with a circadian rhythm disorder;
• Professional drivers or commercial pilots;
• History of nephrolithiasis;
• More than one lifetime episode of major depression;
• History of bipolar disorder, obsessive compulsive disorder, borderline personality disorder, psychotic depression, schizophrenia, schizoaffective disorder, or any other psychotic disorder; history of any psychiatric hospitalization;
• History of a seizure disorder; concurrent use of any anticonvulsant drug (other than assigned study drug);

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VI-0521	VI-0521	15 mg Phentermine and 92 mg Topiramate
Placebo	placebo	-

Primary Outcome Measures

Name	Time	Method
Change in the Apnea/Hypopnea Index (AHI) Between Baseline and Week 28/Early Term.	between baseline and Week 28	AHI is calculated as the mean number of apnea or hypopnea episodes (each lasting a minimum of 10 second) observed per hour of sleep

Secondary Outcome Measures

Name	Time	Method
Percent Change in Weight From Baseline to Week 28	baseline to week 28

Trial Locations

Locations (1)

Kentucky Research Group; 🇺🇸 Louisville, Kentucky, United States